• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Safety and efficacy of a new academic CD19-directed CAR-T cell for refractory/relapsed non-Hodgkin lymphoma and acute lymphoblastic leukemia in Brazil.

作者信息

Donadel Camila D, De Santis Gil C, Gonçalves Thiago E, Pires Bruno G, Palma Leonardo C, Gava Flavia, Guerino-Cunha Renato Luiz, Faria Joana T B, Silva Gabriela V A, Darrigo-Junior Luiz Guilherme, Fatobene Giancarlo, Rocha Vanderson, Covas Dimas T, Calado Rodrigo T, Clé Diego V

机构信息

Department of Medical Imaging, Hematology and Oncology, Ribeirão Preto Medical School, University of São Paulo (USP), Ribeirão Preto, Brazil.

Department of Pediatrics, Ribeirão Preto Medical School, University of São Paulo (USP), Ribeirão Preto, Brazil.

出版信息

Bone Marrow Transplant. 2024 Jul;59(7):1040-1042. doi: 10.1038/s41409-024-02283-6. Epub 2024 Apr 13.

DOI:10.1038/s41409-024-02283-6
PMID:38615142
Abstract
摘要

相似文献

1
Safety and efficacy of a new academic CD19-directed CAR-T cell for refractory/relapsed non-Hodgkin lymphoma and acute lymphoblastic leukemia in Brazil.一种新型靶向CD19的嵌合抗原受体T细胞在巴西用于难治性/复发性非霍奇金淋巴瘤和急性淋巴细胞白血病的安全性和有效性
Bone Marrow Transplant. 2024 Jul;59(7):1040-1042. doi: 10.1038/s41409-024-02283-6. Epub 2024 Apr 13.
2
Preclinical Assessment of Efficacy and Safety Analysis of CAR-T Cells (ISIKOK-19) Targeting CD19-Expressing B-Cells for the First Turkish Academic Clinical Trial with Relapsed/Refractory ALL and NHL Patients.针对复发/难治性急性淋巴细胞白血病和非霍奇金淋巴瘤患者的首次土耳其学术性临床试验中，靶向表达CD19的B细胞的嵌合抗原受体T细胞（ISIKOK-19）的疗效和安全性分析的临床前评估
Turk J Haematol. 2020 Nov 19;37(4):234-247. doi: 10.4274/tjh.galenos.2020.2020.0070. Epub 2020 Aug 4.
3
CAR T cells: The future is already present.嵌合抗原受体T细胞：未来已来。
Med Clin (Barc). 2019 Apr 5;152(7):281-286. doi: 10.1016/j.medcli.2018.08.015. Epub 2018 Nov 2.
4
Individual Patient Data Meta-Analysis from 16 Trials for Safety Factors in Cytokine Release Syndrome After CAR-T Therapy in Patients with Non-Hodgkin Lymphoma (NHL) and Acute Lymphoblastic Leukemia.16 项临床试验中细胞因子释放综合征安全性因素的个体患者数据分析，用于接受 CAR-T 治疗的非霍奇金淋巴瘤（NHL）和急性淋巴细胞白血病患者。
Adv Ther. 2019 Oct;36(10):2881-2894. doi: 10.1007/s12325-019-01056-8. Epub 2019 Aug 19.
5
CD19-targeted chimeric antigen receptor T-cell therapy for CNS relapsed or refractory acute lymphocytic leukaemia: a post-hoc analysis of pooled data from five clinical trials.针对中枢神经系统复发或难治性急性淋巴细胞白血病的 CD19 靶向嵌合抗原受体 T 细胞疗法：五项临床试验 pooled data 的事后分析。
Lancet Haematol. 2021 Oct;8(10):e711-e722. doi: 10.1016/S2352-3026(21)00238-6.
6
Chimeric antigen receptor T cells for acute lymphoblastic leukemia.嵌合抗原受体 T 细胞治疗急性淋巴细胞白血病。
Am J Hematol. 2019 May;94(S1):S24-S27. doi: 10.1002/ajh.25442. Epub 2019 Mar 22.
7
Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia.新型抗 CD19 嵌合抗原受体构建的 CD19 CAR T 在复发或难治性急性淋巴细胞白血病中的疗效和安全性。
J Hematol Oncol. 2020 Sep 7;13(1):122. doi: 10.1186/s13045-020-00953-8.
8
Head-to-head comparison of in-house produced CD19 CAR-T cell in ALL and NHL patients.在 ALL 和 NHL 患者中比较自制 CD19 CAR-T 细胞。
J Immunother Cancer. 2020 Mar;8(1). doi: 10.1136/jitc-2019-000148.
9
CAR-T Cell Therapy for Acute Lymphoblastic Leukemia: Transforming the Treatment of Relapsed and Refractory Disease.嵌合抗原受体T细胞疗法治疗急性淋巴细胞白血病：改变复发难治性疾病的治疗方式
Curr Hematol Malig Rep. 2018 Oct;13(5):396-406. doi: 10.1007/s11899-018-0470-x.
10
Pseudoprogression of extramedullary disease in relapsed acute lymphoblastic leukemia after CAR T-cell therapy.CAR T 细胞治疗后复发急性淋巴细胞白血病髓外疾病的假性进展。
Immunotherapy. 2021 Jan;13(1):5-10. doi: 10.2217/imt-2020-0188. Epub 2020 Oct 12.

引用本文的文献

1
Engineered CAR-NK Cells for Cancer Immunotherapy: Lentiviral-Based CAR Transduction of NK-92 Cells.用于癌症免疫治疗的工程化嵌合抗原受体自然杀伤细胞：基于慢病毒的NK-92细胞嵌合抗原受体转导
Methods Mol Biol. 2025;2930:267-275. doi: 10.1007/978-1-0716-4558-1_19.
2
Post-stem cell transplant maintenance for pediatric acute leukemias: insights from a Brazilian institution with a Latin American perspective.儿童急性白血病干细胞移植后的维持治疗：来自一家巴西机构的见解及拉丁美洲视角
Front Oncol. 2025 Mar 5;15:1540158. doi: 10.3389/fonc.2025.1540158. eCollection 2025.
3
Clinical trials to gene therapy development and production in Brazil: a review.

本文引用的文献

1
Cytomegalovirus reactivation after CD19 CAR T-cell therapy is clinically significant.CD19嵌合抗原受体T细胞疗法后巨细胞病毒再激活具有临床意义。
Haematologica. 2023 Feb 1;108(2):615-620. doi: 10.3324/haematol.2022.281719.
2
Diffuse Large B-Cell Lymphoma.弥漫性大 B 细胞淋巴瘤。
N Engl J Med. 2021 Mar 4;384(9):842-858. doi: 10.1056/NEJMra2027612.
3
Practical guidelines for monitoring and management of coagulopathy following tisagenlecleucel CAR T-cell therapy.嵌合抗原受体 T 细胞疗法后凝血功能障碍监测和管理的实用指南。
巴西基因治疗研发与生产的临床试验综述
Lancet Reg Health Am. 2025 Jan 30;43:100995. doi: 10.1016/j.lana.2025.100995. eCollection 2025 Mar.
Blood Adv. 2021 Jan 26;5(2):593-601. doi: 10.1182/bloodadvances.2020002757.
4
Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.西达基奥仑赛治疗复发或难治性大 B 细胞淋巴瘤患者的疗效和安全性（TRANSCEND NHL 001）：一项多中心无缝设计研究。
Lancet. 2020 Sep 19;396(10254):839-852. doi: 10.1016/S0140-6736(20)31366-0. Epub 2020 Sep 1.
5
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial.阿基仑赛注射液治疗难治性大 B 细胞淋巴瘤的长期安全性和疗效（ZUMA-1）：一项单臂、多中心、1-2 期临床试验。
Lancet Oncol. 2019 Jan;20(1):31-42. doi: 10.1016/S1470-2045(18)30864-7. Epub 2018 Dec 2.
6
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma.Tisagenlecleucel 治疗成人复发或难治性弥漫性大 B 细胞淋巴瘤。
N Engl J Med. 2019 Jan 3;380(1):45-56. doi: 10.1056/NEJMoa1804980. Epub 2018 Dec 1.
7
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia.替沙格赛定用于治疗儿童和年轻成人B细胞淋巴细胞白血病
N Engl J Med. 2018 Feb 1;378(5):439-448. doi: 10.1056/NEJMoa1709866.